Loading...

Thomas Kipps

Title(s)Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Columbia College of Columbia University, New York, NYBS1974Biochemistry
    Harvard Medical School, Boston, MAPh.D.1979Immunology
    Collapse Awards and Honors
    UC San Diego School of Medicine2004Evelyn and Edwin Tasch Chair in Cancer Research

    Collapse Overview 
    Collapse Overview
    Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.

    Dr. Kipps has a national and international reputation for his work in cancer research, immunology, and gene therapy. He has been a leader in the field for many years, and has helped to develop standardized treatment protocols. He is the author of more than 300 publications and is the PI on several peer-reviewed grants, including an award from NCI/NIH to fund the Chronic Lymphocytic Leukemia Research Consortium (CRC). The CRC involves collaboration with eight other Cancer Centers around the United States and the UK. Dr. Kipps is also the Director of the Blood Cancer Research Fund at the UC San Diego Moores Cancer Center. The Blood Cancer Research Fund concentrates on developing cures for all types of blood related cancers, specifically Chronic Lymphocytic Leukemia (CLL).

    Dr. Kipps has over 20 years’ experience in combining research and clinical care responsibilities. As deputy director of research operations, Dr. Kipps is working to further integrate basic and translational research investigators at the Moores Cancer Center with clinical investigators, epidemiologists, and physicians offering state-of-the art therapies for patients with various forms of cancer.

    Research Interests
    A major focus of Dr. Kipps’ research is the immunobiology and genetics of human B-cell malignancies, with emphasis on chronic lymphocytic leukemia (CLL). Dr. Kipps’ work has provided insight into the ontogeny of B cells that are subject to leukemia transformation and defined the highly restricted nature of the immunoglobulins expressed in this disease. In addition, he has defined genetic factors that contribute to the development and progression of this disease, identified biochemical pathways that enhance the growth or survival of leukemia B cells, identified means with which to elicit host anti-leukemia immune responses through vaccines generated via gene transfer, and identified promising new drugs and biologic agents that have activity in the treatment of this disease. He has made seminal observations on how the microenvironment can promote survival of CLL cells and defined strategies for mitigating the protective effects of the microenvironment on CLL cells survival in vivo. He has instigated and enabled work on selected leukemia cell samples of patients with sporadic or familial CLL that led to discovery of the role played by microRNA and ultraconserved, non-coding RNAs in the pathogenesis or progression of CLL in collaborations with the laboratory of Dr. Carlo Croce of the CLL Research Consortium (CRC). In other collaborations initiated through the CRC, Dr. Kipps also contributed to work on the epigenetic factors that contribute to pathogenesis in CLL.

    The study on CLL cells serially collected from patients at time points before therapy, during therapy, or after relapse from therapy allows for investigation of the genetic and biologic features associated with tumor progression, therapeutic response, or resistance to therapy. Discovery of features that distinguish CLL from their normal cell counterparts has helped identify new targets for therapy and/or define surrogate markers associated with more rapid rates of cancer progression or resistance to standard therapy. These studies are integrated with a clinical investigative program that attracts patients seeking improved modalities of treatment for CLL. From this, Dr. Kipps has identified molecular markers that can segregate patients into subgroups that have different risks for disease-progression or different probabilities of response to conventional treatment. This also has allowed for testing the safety and relative efficacy of novel agents developed for treatment of all patients with CLL or subgroups of patients hypothesized to have the best potential response to novel forms of therapy.

    Most recently, Dr. Kipps has discovered that the embryonic antigen ROR1 is expressed on CLL. ROR1 an embryonic type I membrane receptor tyrosine kinase-like surface protein. ROR1 was not expressed on normal, healthy adult tissues, but was found on the leukemia cells of virtually all cases of CLL and on the neoplastic cells of many patients with solid tumors. His work has demonstrated that patients immunized with autologous CLL cells transfected to express the CD40-ligand (CD154) can generate antibodies that are specific for this type I tyrosine kinase that apparently can block its capacity to function as a survival receptor for wnt5a. This work potentially could lead to development of novel vaccines for patients with this disease. Currently, Dr. Kipps is collaborating with other investigators at the UC San Diego Moores Cancer Center on developing monoclonal and recombinant antibodies specific for ROR1 and have identified one that can interfere with ROR1 signaling. The California Institute of Regenerative Medicine (CIRM) is funding this work.

    Another project undertaken in the Kipps’ lab is to define the nature of immunoglobulin gene expression in normal and neoplastic B cells and to examine the relationship between B-cell receptor signaling events and mechanisms governing the pathogenesis and/or progression of CLL. In addition he is investigating the role of the microenvironment in support both normal and neoplastic B cell survival. In addition to his laboratory research, Dr. Kipps is actively involved in clinical research; having developed and/or conducted several phase I and phase II clinical trials.

    Collapse Research 
    Collapse Research Activities and Funding
    Non-canonical Wnt-Receptor Signaling and Targeted Therapies
    NIH R01CA236361Apr 15, 2019 - Mar 31, 2024
    Role: Principal Investigator
    PCYC Karyotype
    Pharmacyclics, Inc. Jun 1, 2018 - Dec 31, 2021
    PCYC Clonal Evolution
    Pharmacyclics, Inc. Feb 21, 2018 - Feb 20, 2021
    Role: Principal Investigator
    A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers
    California Institute for Regenerative Medicine (CIRM) CLIN2-10192Oct 1, 2017 - Jun 30, 2022
    Role: Principal Investigator
    Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies
    California Institute for Regenerative Medicine (CIRM) TRAN1-10258Oct 1, 2017 - Mar 31, 2020
    Role: Co-Investigator
    Oncternal Research Agreement
    Oncternal Therapeutics, Inc. Sep 1, 2016 - Aug 31, 2021
    Role: Principal Investigator
    Oncternal Therapeutics, Inc. HRPP #140141Apr 1, 2016 - Sep 26, 2018
    Role: Principal Investigator
    ROR1 Expression in Human Breast Cancer
    Breast Cancer Research Foundation BCRF-18-123Oct 1, 2014 - Sep 30, 2019
    Role: Co-Investigator
    Protein-Coding and Non-Coding RNA Biomarkers for early detection of CLL
    MD Anderson Texas R01CA182905Jun 1, 2014 - May 31, 2019
    Role: Sub-Site Principal Investigator
    Cancer Center Support Grant (CCSG)
    NIH/NCI P30 CA23100-28May 1, 2014 - Apr 30, 2024
    Role: Senior Deputy Director, Co-Principal Investigator
    Specific Targets for Therapy of Patients with Chronic Lymphocytic Leukemia
    The Leukemia & Lymphoma Society 7005-14Oct 1, 2013 - Sep 30, 2018
    Role: Principal Investigator
    Chronic Lymphocytic Leukemia Research Consortium
    NIH/NCI 5P01CA081534-14Sep 24, 2012 - Aug 31, 2018
    Role: Principal Investigator
    Center of Nanotechnology for Treatment, Understanding, *
    NIH U54CA119335Sep 1, 2009 - Dec 31, 2011
    Role: Co-Investigator
    Lenalidomide Treatment and the Chronic Lymphocytic Leukemia Microenvironment
    NIH R21CA135681Mar 1, 2009 - Feb 28, 2011
    Role: Principal Investigator
    Chronic Lymphocytic Leukemia Research Consortium
    NIH P01CA081534May 1, 1999 - Aug 31, 2018
    Role: Principal Investigator
    CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    NIH P20CA081534May 1, 1999 - Apr 30, 2000
    Role: Principal Investigator
    MOLECULAR THERAPEUTICS OF RHEUMATOID ARTHRITIS
    NIH/NIAMS P50AR044850Sep 28, 1998 - Aug 31, 2004
    Role: Co-Investigator
    General Clinical Research Center
    NIH M01RR000827Jan 27, 1997 - Nov 30, 2010
    Role: Co-Investigator
    ERB 2NEU DNA VACCINES FOR BREAST CANCER IMMUNOTHERAPY
    NIH R01CA066000Sep 1, 1995 - Aug 31, 1998
    Role: Principal Investigator
    IMMUNOBIOLOGY OF AIDS LYMPHOMAS
    NIH R01CA065408Jul 25, 1994 - Jun 30, 1998
    Role: Principal Investigator
    NEW MODALITIES FOR ACTIVE IMMUNOTHERAPY OF MALIGNANCIES
    NIH R01CA057868Aug 25, 1992 - Jul 31, 1994
    Role: Principal Investigator
    NOVEL THERAPEUTIC APPROACHES IN HIV-ASSOCIATED LYMPHOMAS
    NIH R01CA055513Jul 16, 1991 - Jun 30, 1994
    Role: Principal Investigator
    MECHANISMS OF AIDS-ASSOCIATED LYMPHOMAGENESIS
    NIH R01CA054755Mar 14, 1991 - Feb 28, 1995
    Role: Principal Investigator
    Antibody V Gene Expression B Cell Lymphocytic Leukemia
    NIH R37CA049870May 1, 1989 - Jul 31, 2015
    Role: Principal Investigator
    ANTIBODY V GENE EXPRESSION IN HUMAN B CELL MALIGNANCIES
    NIH R01CA049870May 1, 1989 - Jun 30, 1990
    Role: Principal Investigator
    MULTIPARAMETER FLUORESCENCE ACTIVATED CELL SORTER
    NIH S10RR004051Apr 18, 1988 - Apr 17, 1990
    Role: Principal Investigator
    MULTIPURPOSE ARTHRITIS CENTER
    NIH P60AR033489Feb 1, 1987 - Jun 30, 1990
    Role: Co-Investigator
    HUMAN ANTIBODY DIVERSITY IN HEALTH &AUTOIMMUNITY
    NIH R29AR038475Aug 1, 1986 - Jul 31, 1992
    Role: Principal Investigator
    IMMUNOLOGIC AGING AND AUTOIMMUNITY
    NIH R01AG004100Jul 1, 1983 - Aug 31, 1996
    Role: Principal Investigator
    IMMUNOLOGIC AGING AND AUTOIMMUNITY
    NIH R55AG004100Jul 1, 1983 - Aug 31, 1992
    Role: Principal Investigator
    Specialized Cancer Center Support Grant
    NIH P30CA023100Apr 1, 1978 - Nov 30, 1991
    Role: Principal Investigator
    GENERAL CLINICAL RESEARCH CENTER
    NIH M01RR000833Dec 1, 1977 - Sep 30, 2005
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021 Feb 05; 102:106520. Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, Mongan A. PMID: 33611131.
      View in: PubMed   Mentions:    Fields:    
    2. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J Hematol Oncol. 2021 Jan 15; 14(1):17. Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R. PMID: 33451349.
      View in: PubMed   Mentions:    Fields:    
    3. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 Jan; 2(1):54-69. PMID: 33604581.
      View in: PubMed   Mentions:
    4. miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors. Blood. 2020 11 10. Sharma S, Pavlasova GM, Seda V, Cerna KA, Vojackova E, Filip D, Ondrisova L, Sandova V, Kostalova L, Zeni PF, Borsky M, Oppelt J, Liskova K, Kren L, Janikova A, Pospisilova S, Fernandes SM, Shehata M, Rassenti LZ, Jaeger U, Doubek M, Davids MS, Brown JR, Mayer J, Kipps TJ, Mraz M. PMID: 33171493.
      View in: PubMed   Mentions:    Fields:    
    5. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. Leukemia. 2020 Oct 23. Hasan MK, Ghia EM, Rassenti LZ, Widhopf GF, Kipps TJ. PMID: 33097837.
      View in: PubMed   Mentions:    Fields:    
    6. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020 Dec 01; 38(34):4042-4054. Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. PMID: 32986498.
      View in: PubMed   Mentions: 3     Fields:    
    7. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 Sep 16; 12(561). Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, Rassenti LZ, Kipps TJ, Brown JR, Getz G, Ho VT, Gnirke A, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Kharchenko PV, Wu CJ. PMID: 32938797.
      View in: PubMed   Mentions:    Fields:    
    8. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 09; 21(9):1188-1200. Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. PMID: 32888452.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    9. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 10; 97:106432. Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. PMID: 32911375.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    10. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 02; 18(2):185-217. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. PMID: 32023533.
      View in: PubMed   Mentions: 3     Fields:    
    11. Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. Oncogene. 2020 03; 39(12):2550-2567. Zhang J, Lin X, Wu L, Huang JJ, Jiang WQ, Kipps TJ, Zhang S. PMID: 31996785.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    12. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Cell Death Differ. 2020 Jul; 27(7):2206-2216. Sanchez-Lopez E, Ghia EM, Antonucci L, Sharma N, Rassenti LZ, Xu J, Sun B, Kipps TJ, Karin M. PMID: 31992855.
      View in: PubMed   Mentions: 3     Fields:    
    13. Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. J Hematol Oncol. 2019 11 19; 12(1):114. Ramassone A, D'Argenio A, Veronese A, Basti A, Soliman SHA, Volinia S, Bassi C, Pagotto S, Ferracin M, Lupini L, Saccenti E, Balatti V, Pepe F, Rassenti LZ, Innocenti I, Autore F, Marzetti L, Mariani-Costantini R, Kipps TJ, Negrini M, Laurenti L, Visone R. PMID: 31744508.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2019 11 26; 116(48):24252-24258. Veneziano D, Tomasello L, Balatti V, Palamarchuk A, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. PMID: 31723042.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    15. Targeted Therapy in Chronic Lymphocytic Leukemia. Cancer J. 2019 Nov/Dec; 25(6):378-385. Kipps TJ, Choi MY. PMID: 31764118.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    16. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. NPJ Breast Cancer. 2019; 5:35. Hasan MK, Widhopf GF, Zhang S, Lam SM, Shen Z, Briggs SP, Parker BA, Kipps TJ. PMID: 31667337.
      View in: PubMed   Mentions:
    17. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798. Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. PMID: 31628428.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    18. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 12; 94(12):1353-1363. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. PMID: 31512258.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    19. Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. Target Oncol. 2019 10; 14(5):551-561. Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR. PMID: 31473933.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    20. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. 2020 04; 105(4):e164-e168. Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. PMID: 31413095.
      View in: PubMed   Mentions:    Fields:    
    21. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019 09 26; 134(13):1084-1094. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. PMID: 31409670.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    22. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(14):3461-3469. Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA. PMID: 31352850.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    23. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6. Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M. PMID: 31447270.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    24. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 08 22; 134(8):688-698. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. PMID: 31292113.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    25. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. PMID: 31196847.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    26. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019 Jun 06; 380(23):2225-2236. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. PMID: 31166681.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    27. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479. Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ. PMID: 31142838.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    28. SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):321-325. Choi MY, Wang HY, Kipps TJ. PMID: 31204237.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2020 01; 105(1):e22-e25. Lujan JV, Lengerke-Diaz PA, Jacobs C, Moreno-Cortes EF, Ramirez-Segura CA, Choi MY, McCarthy C, Heinen A, Kipps TJ, Castro JE. PMID: 31048356.
      View in: PubMed   Mentions: 1     Fields:    
    30. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 07 11; 134(2):111-122. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. PMID: 31023700.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    31. HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. Cancers (Basel). 2019 Apr 23; 11(4). Pagotto S, Veronese A, Soranno A, Balatti V, Ramassone A, Guanciali-Franchi PE, Palka G, Innocenti I, Autore F, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R. PMID: 31018621.
      View in: PubMed   Mentions:
    32. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. PMID: 30995176.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    33. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174. Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. PMID: 30967392.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    34. Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. Blood. 2019 06 20; 133(25):2651-2663. Ghia EM, Rassenti LZ, Neuberg DS, Blanco A, Yousif F, Smith EN, McPherson JD, Hudson TJ, Harismendy O, Frazer KA, Kipps TJ. PMID: 30923040.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    35. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 06 27; 133(26):2765-2775. Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. PMID: 30862645.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    36. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. PMID: 30767298.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    37. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 05 09; 133(19):2031-2042. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. PMID: 30842083.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    38. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 07; 186(1):184-188. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. PMID: 30740654.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 02 11; 35(2):283-296.e5. Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, Ten Hacken E, Taylor-Weiner A, Rassenti LZ, Ghia EM, Kipps TJ, Obeng EA, Cibulskis CL, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestner A, Leshchiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L. PMID: 30712845.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    40. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci U S A. 2019 01 22; 116(4):1370-1377. Zhang S, Zhang H, Ghia EM, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B, Widhopf GF, Yu J, Schwab R, Messer K, Jiang W, Parker BA, Carson DA, Kipps TJ. PMID: 30622177.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    41. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan; 17(1):12-20. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. PMID: 30659125.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    42. Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood. 2019 02 28; 133(9):990-992. Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ. PMID: 30593446.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    43. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2019 03; 33(3):653-661. Hasan MK, Rassenti L, Widhopf GF, Yu J, Kipps TJ. PMID: 30568170.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    44. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019 02 01; 37(4):269-277. Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. PMID: 30523712.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    45. SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. Br J Haematol. 2019 02; 184(4):605-615. Brander DM, Friedman DR, Volkheimer AD, Christensen DJ, Rassenti LZ, Kipps TJ, Guadalupe E, Chen Y, Zhang D, Wang X, Davis C, Owzar K, Weinberg JB. PMID: 30443898.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    46. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol. 2018 11; 93(11):1402-1410. Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. PMID: 30129285.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    47. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. PMID: 30282833.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    48. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019 04; 60(4):1000-1005. Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ. PMID: 30277101.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    49. miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 2018 11 15; 132(20):2179-2182. Balatti V, Tomasello L, Rassenti LZ, Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y, Croce CM. PMID: 30242085.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    50. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 09; 103(9):1502-1510. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. PMID: 29880603.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    51. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. PMID: 29859176.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    52. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget. 2018 May 15; 9(37):24731-24736. Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF, Kipps TJ. PMID: 29872501.
      View in: PubMed   Mentions: 6     Fields:    
    53. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 05 01; 4(5):712-716. O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. PMID: 29470582.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    54. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018 07 12; 132(2):170-178. Hasan MK, Yu J, Widhopf GF, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps TJ. PMID: 29678828.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    55. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018 Mar 22; 378(12):1107-1120. PMID: 29562156.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCTClinical Trials
    56. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 06 21; 131(25):2745-2760. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. PMID: 29540348.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    57. Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. Cell Rep. 2018 02 13; 22(7):1875-1888. PMID: 29444438.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    58. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):114-124.e2. Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP. PMID: 29352719.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    59. Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2018 06; 103(6):e249-e251. PMID: 29170253.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    60. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 11; 15(11):1414-1427. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. PMID: 29118233.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    61. Corrigendum to "Wnt5a Signaling in Normal and Cancer Stem Cells". Stem Cells Int. 2017; 2017:3467360. Zhou Y, Kipps TJ, Zhang S. PMID: 29098008.
      View in: PubMed   Mentions:
    62. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10731-10736. Rassenti LZ, Balatti V, Ghia EM, Palamarchuk A, Tomasello L, Fadda P, Pekarsky Y, Widhopf GF, Kipps TJ, Croce CM. PMID: 28923920.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    63. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 10; 102(10):1796-1805. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. PMID: 28751558.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    64. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 01; 32(1):83-91. PMID: 28592889.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    65. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017 05 19; 10(1):112. Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE. PMID: 28526063.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    66. Wnt5a induces ROR1 to associate with 14-3-3? for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017 12; 31(12):2608-2614. PMID: 28465528.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    67. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017 12; 31(12):2615-2622. PMID: 28465529.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    68. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget. 2017 Apr 18; 8(16):25942-25954. Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A, Blachly JS, Zhang X, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps TJ, Sampath D, Coombes KR, Hertlein EK. PMID: 28412730.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    69. Wnt5a Signaling in Normal and Cancer Stem Cells. Stem Cells Int. 2017; 2017:5295286. PMID: 28491097.
      View in: PubMed   Mentions:
    70. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291. PMID: 28397242.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    71. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705. Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. PMID: 28325865.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    72. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 02 09; 3:17008. PMID: 28179635.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    73. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia. 2017 06; 31(6):1348-1354. PMID: 28115735.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    74. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 01 19; 3:16096. PMID: 28102226.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    75. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10; 35(8):826-833. PMID: 28095146.
      View in: PubMed   Mentions: 112     Fields:    Translation:Humans
    76. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240. PMID: 28089635.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    77. hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. ACS Chem Biol. 2017 02 17; 12(2):444-455. PMID: 28026162.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    78. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017 06; 31(6):1333-1339. PMID: 27904138.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    79. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia. 2017 07; 31(7):1547-1554. PMID: 27890934.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    80. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175(5):892-903. PMID: 27861736.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    81. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940. PMID: 27815263.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    82. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763. PMID: 27818134.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    83. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol. 2018 02; 180(4):597-600. PMID: 27766619.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. How Do Targeted Therapies Change the Management of Indolent Lymphomas? Oncology (Williston Park). 2016 09 15; 30(9):859-60. PMID: 27633418.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. Oncotarget. 2016 08 23; 7(34):54174-54182. PMID: 27527866.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    86. Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. Best Pract Res Clin Haematol. 2016 03; 29(1):15-29. PMID: 27742068.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    87. Selectivity in Small Molecule Splicing Modulation. ACS Chem Biol. 2016 10 21; 11(10):2716-2723. PMID: 27499047.
      View in: PubMed   Mentions: 7     Fields:    Translation:Cells
    88. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13. PMID: 27480113.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    89. ATM Mutations in Cancer: Therapeutic Implications. . 2016 08; 15(8):1781-91. PMID: 27413114.
      View in: PubMed   Mentions:
    90. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma. 2017 02; 58(2):348-356. PMID: 27389174.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    91. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. PMID: 27247136.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    92. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8. PMID: 27151992.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    93. Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. Int J Hematol Oncol. 2016 May; 5(1):27-35. Manouchehri S, Ibsen S, Wright J, Rassenti L, Ghia EM, Widhopf GF, Kipps TJ, Heller MJ. PMID: 30302201.
      View in: PubMed   Mentions:
    94. The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands. ChemMedChem. 2016 05 19; 11(10):1097-106. PMID: 27144715.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    95. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 04 21; 374(16):1594-5. PMID: 27096594.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    96. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci U S A. 2016 May 03; 113(18):5071-6. PMID: 27071132.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    97. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11; 6:e404. PMID: 26967821.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    98. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol. 2016 Apr; 173(1):105-13. PMID: 26848054.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    99. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016 Feb; 126(2):585-98. PMID: 26690702.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    100. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19; 7(3):2809-22. PMID: 26646452.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    101. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016 Mar; 48(3):253-64. PMID: 26780610.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCells
    102. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016; 57(6):1291-9. PMID: 26763349.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    103. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016 Apr; 30(4):929-36. PMID: 26639181.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    104. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25):2425-37. PMID: 26639149.
      View in: PubMed   Mentions: 285     Fields:    Translation:HumansCTClinical Trials
    105. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22. PMID: 26639348.
      View in: PubMed   Mentions: 392     Fields:    Translation:HumansCTClinical Trials
    106. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94. PMID: 26472751.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    107. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016 Jan 07; 127(1):79-86. PMID: 26472752.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    108. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget. 2015 Sep 22; 6(28):24599-610. PMID: 26337206.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    109. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2819-25. PMID: 25721750.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    110. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    111. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. PMID: 26297272.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    112. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One. 2015; 10(6):e0128151. PMID: 26030772.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    113. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2826-33. PMID: 25797560.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    114. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. . 2015 Jul; 14(7):1650-60. PMID: 25934707.
      View in: PubMed   Mentions:
    115. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Jun; 2(6):572-82. PMID: 26288818.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    116. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015 Apr 10; 5:e303. PMID: 25860294.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    117. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica. 2015 Jul; 100(7):945-54. PMID: 25862704.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    118. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Apr 07; 112(14):4322-7. PMID: 25787252.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    119. Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015 Mar; 11(3):e1004105. PMID: 25768983.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    120. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug; 100(8):e311-4. PMID: 25769539.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    121. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30; 125(18):2779-85. PMID: 25769620.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    122. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; 39(5):495-500. PMID: 25804339.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    123. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Feb 17; 112(7):2169-74. PMID: 25646413.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    124. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget. 2015 Jan 30; 6(3):1884-8. PMID: 25595892.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    125. Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan; 26(1):14-25. PMID: 25382101.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    126. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1878-80. PMID: 25311497.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    127. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):17266-71. PMID: 25411317.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    128. Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Blood Cancer J. 2014 Nov 14; 4:e258. PMID: 25397619.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    129. Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. Genome Biol. 2014 Aug 07; 15(8):420. PMID: 25103687.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    130. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014 Sep 04; 124(10):1637-44. PMID: 24990888.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    131. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014 Jul 24; 124(4):546-54. PMID: 24914134.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    132. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17; 371(3):213-23. PMID: 24881631.
      View in: PubMed   Mentions: 386     Fields:    Translation:Humans
    133. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 01; 32(19):2067-73. PMID: 24868031.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    134. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 03; 124(1):42-8. PMID: 24868078.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    135. Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line. Int J Mol Sci. 2014 May 27; 15(6):9407-21. PMID: 24871368.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    136. Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood. 2014 Jul 10; 124(2):259-62. PMID: 24855209.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    137. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood. 2014 Jun 26; 123(26):4101-10. PMID: 24829201.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    138. Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis. 2014 Jul; 35(12-13):1828-36. PMID: 24723219.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    139. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014 Jul 03; 124(1):84-95. PMID: 24787006.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    140. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia. 2015 Jan; 29(1):86-95. PMID: 24732594.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    141. Repetition in visual word identification: benefits and costs. Q J Exp Psychol (Hove). 2014 Oct; 67(10):1986-2009. PMID: 25248100.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    142. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014 Feb 20; 506(7488):328-33. PMID: 24522528.
      View in: PubMed   Mentions: 444     Fields:    Translation:HumansAnimalsCells
    143. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13; 370(11):997-1007. PMID: 24450857.
      View in: PubMed   Mentions: 446     Fields:    Translation:HumansCTClinical Trials
    144. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014 Mar 20; 123(12):1810-7. PMID: 24415539.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCells
    145. ROR1 can interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic mice. Proc Natl Acad Sci U S A. 2014 Jan 14; 111(2):793-8. PMID: 24379361.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    146. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014 Mar; 4(3):348-61. PMID: 24356097.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    147. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem. 2014 Mar; 60(3):500-9. PMID: 24270796.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    148. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood. 2013 Dec 05; 122(24):3960-3. PMID: 24100449.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    149. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014; 9:103-18. PMID: 23987584.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    150. Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J Med Chem. 2013 Sep 12; 56(17):6576-82. PMID: 23919277.
      View in: PubMed   Mentions: 7     Fields:    Translation:Cells
    151. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9. PMID: 23821659.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    152. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74. PMID: 23810245.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    153. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One. 2013; 8(6):e65203. PMID: 23840319.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    154. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013 Jun 15; 73(12):3649-60. PMID: 23771907.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    155. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Aug; 54(8):1836-9. PMID: 23597135.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    156. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70. PMID: 23645694.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    157. Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. Electrophoresis. 2013 Apr; 34(7):1076-84. PMID: 23436471.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    158. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6127-32. PMID: 23530247.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    159. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia. 2013 Apr; 27(5):1214-7. PMID: 23337928.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    160. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013 Feb 07; 121(6):971-4. PMID: 23255557.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    161. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013 Jan 10; 121(2):351-9. PMID: 23160471.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    162. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012 Dec; 181(6):1903-10. PMID: 23041612.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    163. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct; 18(5):404-10. PMID: 23006944.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    164. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia. 2013 Mar; 27(3):740-3. PMID: 22902365.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    165. Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Feb; 54(2):400-2. PMID: 22784365.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    166. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012 Sep 27; 120(13):2639-49. PMID: 22837534.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    167. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10; 30(23):2820-2. PMID: 22778323.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    168. Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood. 2012 Aug 23; 120(8):1687-90. PMID: 22745306.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    169. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood. 2012 Sep 27; 120(13):2631-8. PMID: 22723551.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    170. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Nov; 53(11):2136-42. PMID: 22475052.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    171. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012 Jul 10; 30(20):2483-91. PMID: 22564988.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    172. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. 2012 Jun 15; 72(12):2937-48. PMID: 22505652.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    173. Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. Leuk Lymphoma. 2012 Sep; 53(9):1835-8. PMID: 22335532.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    174. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression. Cancer Gene Ther. 2012 May; 19(5):336-44. PMID: 22402624.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    175. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012; 7(3):e31127. PMID: 22403610.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansAnimalsCells
    176. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med. 2012 Feb 10; 18:19-28. PMID: 21979753.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    177. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2012 Feb 14; 109(7):2555-60. PMID: 22308499.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    178. Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL). Leukemia. 2012 Jul; 26(7):1689-92. PMID: 22237780.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    179. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood. 2012 Mar 08; 119(10):2293-301. PMID: 22234695.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    180. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed). 2012 Jan 01; 4:61-73. PMID: 22202043.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    181. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10; 30(5):488-96. PMID: 22184378.
      View in: PubMed   Mentions: 271     Fields:    Translation:HumansCTClinical Trials
    182. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012 Jan 12; 119(2):329-31. PMID: 22086416.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    183. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. Blood. 2012 Jan 05; 119(1):180-7. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, Costinean S, Rassenti LZ, Nakamura T, Kipps TJ, Aqeilan RI, Pekarsky Y, Trapasso F, Croce CM. PMID: 22065599.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    184. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011 Oct; 35(10):1390-4. PMID: 21813176.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    185. Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease. J Hum Genet. 2011 Sep; 56(9):676-81. Peiró AM, Tang CM, Murray F, Zhang L, Brown LM, Chou D, Rassenti L, Kipps TJ, Kipps TA, Insel PA. PMID: 21796143.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    186. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 09; 108(32):13253-7. PMID: 21788521.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCells
    187. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011 Sep 08; 118(10):2827-9. PMID: 21791429.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    188. Rituximab in chronic lymphocytic leukemia. Adv Ther. 2011 Jul; 28(7):534-54. PMID: 21725721.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    189. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011 Sep 15; 118(11):3072-9. PMID: 21636858.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    190. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. Leuk Res. 2011 Jul; 35(7):965-7. Messmer BT, Nour-Omid TS, Ghia E, Sanchez AB, Kipps TJ. PMID: 21570119.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    191. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. J Immunol. 2011 Jun 01; 186(11):6338-44. Ghia EM, Widhopf GF, Rassenti LZ, Kipps TJ. PMID: 21525382.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    192. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16; 117(24):6450-8. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA. PMID: 21498674.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    193. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Haematol. 2011 May; 86(5):405-411. Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps TJ. PMID: 21323738.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    194. Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles. Leukemia. 2011 May; 25(5):883-8. PMID: 21321570.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    195. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011 Sep 01; 129(5):1162-9. PMID: 21120911.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    196. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 05; 305(1):59-67. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. PMID: 21205967.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCells
    197. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec; 203(2):134-40. Heerema NA, Byrd JC, Dal Cin PS, Dell' Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL. PMID: 21156225.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    198. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8. PMID: 21156226.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    199. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec; 203(2):161-8. PMID: 21156228.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    200. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. PMID: 21115978.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    201. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011 Jan 20; 117(3):882-9. PMID: 21079155.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    202. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2010 Nov 02; 107(44):18956-60. Zhang W, Kater AP, Widhopf GF, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ. PMID: 20956327.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    203. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010 Nov; 24(11):1893-900. Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, Prussak CE, Keating M, Kipps TJ. PMID: 20882050.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    204. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov; 151(4):336-45. Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. PMID: 20812997.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    205. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM. PMID: 20806349.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    206. Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events. Clin Adv Hematol Oncol. 2010 Aug; 8(8):suppl 1-15. Chanan-Khan A, Kipps T, Stilgenbauer S. PMID: 21192630.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    207. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS One. 2010 Jul 22; 5(7):e11716. O'Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein PC, Handel TM. PMID: 20661426.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    208. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A. 2010 Jul 06; 107(27):12210-5. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. PMID: 20566844.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    209. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010 May; 20(5):589-99. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. PMID: 20439436.
      View in: PubMed   Mentions: 146     Fields:    Translation:HumansAnimalsCells
    210. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol. 2010 Apr 23; 3(4):448-57. Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY. PMID: 20490336.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    211. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010 May 20; 28(15):2529-37. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC, De Vos J, Hernández JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foà R. PMID: 20406941.
      View in: PubMed   Mentions: 224     Fields:    Translation:Humans
    212. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010 Aug 12; 116(6):945-52. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. PMID: 20393129.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCells
    213. Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C. ACS Chem Biol. 2010 Mar 19; 5(3):287-99. Shi R, Re D, Dudl E, Cuddy M, Okolotowicz KJ, Dahl R, Su Y, Hurder A, Kitada S, Peddibhotla S, Roth GP, Smith LH, Kipps TJ, Cosford N, Cashman J, Reed JC. PMID: 20141195.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    214. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 01; 28(10):1749-55. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A. PMID: 20194866.
      View in: PubMed   Mentions: 167     Fields:    Translation:HumansCTClinical Trials
    215. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol. 2010 Oct; 66(5):919-25. Sanchez AB, Nguyen T, Dema-Ala R, Kummel AC, Kipps TJ, Messmer BT. PMID: 20087593.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    216. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010 May 13; 115(19):3916-22. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. PMID: 20071661.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    217. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009 Dec 14; 4(12):e8294. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ, Carson DA. PMID: 20011538.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    218. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis. 2010 Feb; 31(2):208-15. Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA. PMID: 19926640.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    219. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010 Jan 21; 115(3):489-95. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. PMID: 19843887.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    220. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2010 Jan; 24(1):237-9. Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AM, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. PMID: 19812607.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    221. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009 Nov 12; 114(20):4469-76. Enzler T, Kater AP, Zhang W, Widhopf GF, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ. PMID: 19755673.
      View in: PubMed   Mentions: 27     Fields:    Translation:Animals
    222. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009 Oct 29; 114(18):3872-9. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M, Kipps TJ, Croce CM. PMID: 19717645.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCells
    223. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct; 23(10):1779-89. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. PMID: 19693094.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    224. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell. 2009 Aug 04; 16(2):161-71. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. PMID: 19647226.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    225. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest. 2009 Jun; 39(6):497-506. Steininger C, Rassenti LZ, Vanura K, Eigenberger K, Jäger U, Kipps TJ, Mannhalter C, Stilgenbauer S, Popow-Kraupp T. PMID: 19490058.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    226. The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone. Leukemia. 2009 Jun; 23(6):1182-6. Buhl AM, Novotny GW, Josefsson P, Nielsen JE, Pedersen LB, Geisler C, Rassenti LZ, Kipps TJ, Jurlander J, Leffers H. PMID: 19212335.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    227. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008 Dec 16; 105(50):19643-8. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM. PMID: 19064921.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    228. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 02; 113(14):3168-71. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. PMID: 19050308.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    229. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19532-7. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps TJ, Insel PA. PMID: 19033455.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    230. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 08; 113(2):299-305. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. PMID: 18931344.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCTClinical Trials
    231. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol. 2008 Sep; 142(5):802-7. Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, Gilkes AF, Hofmann WK, Basso G, Dell'orto MC, Foà R, Chiaretti S, De Vos J, Rauhut S, Papenhausen PR, Hernández JM, Lumbreras E, Yeoh AE, Koay ES, Li R, Liu WM, Williams PM, Wieczorek L, Haferlach T. PMID: 18573112.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    232. Genomic complexity in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1550. Kipps TJ. PMID: 18725569.
      View in: PubMed   Mentions: 1     Fields:    
    233. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008 Nov; 22(11):2048-53. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. PMID: 18754025.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    234. Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity. Cancer Gene Ther. 2009 Jan; 16(1):53-64. Rieger R, Whitacre D, Cantwell MJ, Prussak C, Kipps TJ. PMID: 18654609.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    235. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res. 2009 Mar; 33(3):368-76. Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ. PMID: 18640719.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    236. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1923-30. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. PMID: 18577710.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    237. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008 Apr 01; 105(13):5166-71. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 18362358.
      View in: PubMed   Mentions: 273     Fields:    Translation:HumansAnimalsCells
    238. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15; 111(10):5101-8. Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. PMID: 18326815.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    239. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3047-52. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF, Rassenti LZ, Cantwell MJ, Prussak CE, Carson DA, Kipps TJ. PMID: 18287027.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansAnimalsCells
    240. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15; 111(12):5446-56. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. PMID: 18216293.
      View in: PubMed   Mentions: 939     Fields:    Translation:Humans
    241. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. PMID: 18182662.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    242. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol. 2007 Dec; 139(5):709-16. Nicoloso MS, Kipps TJ, Croce CM, Calin GA. PMID: 18021085.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    243. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008 Mar 01; 111(5):2685-92. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps TJ. PMID: 18048647.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    244. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10; 25(35):5556. Kipps TJ. PMID: 17984183.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    245. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007 Sep; 20(3):557-68. Wierda WG, Kipps TJ. PMID: 17707840.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    246. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007 Sep; 20(3):415-24. Kipps TJ. PMID: 17707830.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    247. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007 Sep; 12(3):215-29. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM. PMID: 17785203.
      View in: PubMed   Mentions: 286     Fields:    Translation:HumansCells
    248. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007 Nov 01; 110(9):3326-33. Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps TJ, Keating MJ, Call TG, Catovsky D, Caporaso N, Houlston RS. PMID: 17687107.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    249. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 2008 Mar 15; 111(6):3137-44. Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. PMID: 17675554.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    250. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4448-55. Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. PMID: 17671129.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    251. Cellular immune therapy for chronic lymphocytic leukemia. Blood. 2007 Oct 15; 110(8):2811-8. Kater AP, van Oers MH, Kipps TJ. PMID: 17638850.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    252. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007 Jun 01; 129(5):879-90. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C. PMID: 17540169.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansAnimalsCells
    253. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007 May; 21(5):956-64. Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. PMID: 17361231.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    254. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol. 2007 Mar; 35(3):434-42. Kato K, Chu P, Takahashi S, Hamada H, Kipps TJ. PMID: 17309824.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    255. Alemtuzumab in chronic lymphocytic leukemia. Future Oncol. 2007 Feb; 3(1):29-42. James DF, Kipps TJ. PMID: 17280499.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    256. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006 Dec 15; 66(24):11590-3. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. PMID: 17178851.
      View in: PubMed   Mentions: 243     Fields:    Translation:HumansCells
    257. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2007 Jan; 21(1):169-74. Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I. PMID: 17051241.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    258. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007 Jan 15; 109(2):703-10. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ. PMID: 16973958.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    259. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006 Jul 15; 70(4):209-13. Rassenti LZ, Kipps TJ. PMID: 16906583.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    260. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006 Nov 15; 108(10):3450-7. Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ. PMID: 16741250.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    261. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia. 2006 Apr; 20(4):680-8. Castro JE, Prada CE, Aguillon RA, Kitada S, Fukuda T, Motta M, Wu C, Dicker F, Sun G, Wang JY, Carson DA, Reed JC, Kipps TJ. PMID: 16498393.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    262. CD154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci. 2005 Dec; 1062:51-60. Messmer D, Kipps TJ. PMID: 16461788.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    263. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 01; 107(5):1761-7. Burger JA, Kipps TJ. PMID: 16269611.
      View in: PubMed   Mentions: 385     Fields:    Translation:HumansAnimalsCells
    264. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov; 29(11):1253-7. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. PMID: 15916806.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    265. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005 Oct 27; 353(17):1793-801. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 16251535.
      View in: PubMed   Mentions: 839     Fields:    Translation:HumansCells
    266. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 01; 107(3):859-61. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. PMID: 16223776.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    267. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct; 19(10):1788-93. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG. PMID: 16094420.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    268. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005 Sep 27; 102(39):13944-9. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 16166262.
      View in: PubMed   Mentions: 1232     Fields:    Translation:HumansCells
    269. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6325-32. Wierda WG, Kipps TJ, Keating MJ. PMID: 16155015.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    270. Treatment of solid tumors with immunotoxins. Breast Cancer Res. 2005; 7(5):184-6. Messmer D, Kipps TJ. PMID: 16168135.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    271. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 2005 Oct 01; 106(7):2506-12. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, Kipps TJ. PMID: 15972449.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    272. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood. 2005 Sep 01; 106(5):1742-8. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ. PMID: 15914559.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    273. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005 Sep 01; 106(5):1824-30. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. PMID: 15905192.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    274. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005 Aug 01; 106(3):1012-20. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ, Kipps TJ. PMID: 15860672.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    275. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 2005 Apr 21; 352(16):1667-76. Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. PMID: 15843669.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    276. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 10; 23(17):3877-85. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC, Plass C. PMID: 15809452.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    277. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia. 2005 Mar; 19(3):427-34. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH, Castro JE, Kipps TJ, van Lier RA, van Oers MH, Eldering E. PMID: 15674362.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    278. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol. 2005 Jan 15; 174(2):864-70. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ. PMID: 15634908.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    279. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005 Mar 01; 105(5):2036-41. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, Weiss A, Kipps TJ. PMID: 15514014.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    280. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. PMID: 15329909.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    281. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood. 2005 Apr 15; 105(8):3193-8. Dicker F, Kater AP, Fukuda T, Kipps TJ. PMID: 15339846.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    282. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26; 351(9):893-901. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. PMID: 15329427.
      View in: PubMed   Mentions: 236     Fields:    Translation:HumansCells
    283. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004 Aug 10; 101(32):11755-60. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. PMID: 15284443.
      View in: PubMed   Mentions: 418     Fields:    Translation:HumansCells
    284. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004 Oct 15; 104(8):2499-504. Widhopf GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. PMID: 15217828.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCells
    285. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol. 2004 Mar; 11(3):389-95. Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D, Kipps TJ, Reed JC, Pellecchia M. PMID: 15123268.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    286. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):3118-23. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA. PMID: 14973184.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansCells
    287. Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. J Immunol. 2004 Feb 15; 172(4):2092-9. Widhopf GF, Brinson DC, Kipps TJ, Tighe H. PMID: 14764674.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    288. Retraction: The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells. Blood. 2004 Aug 15; 104(4):932. Pedersen IM, Zapata JM, Samuel T, Scott FL, Salvesen GS, Honda T, Gribble GW, Suh N, Sporn MB, Kipps TJ, Reed JC. PMID: 14739219.
      View in: PubMed   Mentions:    Fields:    
    289. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003 Nov 06; 22(50):8093-101. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA. PMID: 14603250.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    290. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 2003 Jul 15; 63(14):4128-35. Rieger R, Kipps TJ. PMID: 12874017.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    291. Immunobiology of chronic lymphocytic leukemia. Curr Opin Hematol. 2003 Jul; 10(4):312-8. Kipps TJ. PMID: 12799538.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    292. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. Hum Gene Ther. 2003 Jun 10; 14(9):849-60. Wu CC, Castro JE, Motta M, Cottam HB, Kyburz D, Kipps TJ, Corr M, Carson DA. PMID: 12828856.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    293. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003 Jun; 9(6):2166-72. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. PMID: 12796382.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    294. CRC Tissue Core Management System (TCMS): integration of basic science and clinical data for translational research. AMIA Annu Symp Proc. 2003; 853. Greaves AW, Payne PR, Rassenti L, Kipps TJ. PMID: 14728358.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    295. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003; 153-75. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. PMID: 14633781.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    296. CRC Clinical Trials Management System (CTMS): an integrated information management solution for collaborative clinical research. AMIA Annu Symp Proc. 2003; 967. Payne PR, Greaves AW, Kipps TJ. PMID: 14728471.
      View in: PubMed   Mentions: 7     Fields:    
    297. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Nov 26; 99(24):15524-9. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. PMID: 12434020.
      View in: PubMed   Mentions: 1567     Fields:    Translation:HumansCells
    298. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 2002 Oct 15; 100(8):2965-72. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. PMID: 12351409.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    299. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol Ther. 2002 Oct; 6(4):455-63. Tolba KA, Bowers WJ, Eling DJ, Casey AE, Kipps TJ, Federoff HJ, Rosenblatt JD. PMID: 12377186.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    300. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 2002 Sep 01; 100(5):1795-801. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps TJ, Choi YS, Bennett F, Reed JC. PMID: 12176902.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    301. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15; 100(13):4609-14. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. PMID: 12393534.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansCells
    302. Immune and cell therapy of hematologic malignancies. Int J Hematol. 2002 Aug; 76 Suppl 1:269-73. Kipps TJ. PMID: 12430862.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    303. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br J Haematol. 2002 Aug; 118(2):506-13. Bashey A, Cantwell MJ, Kipps TJ. PMID: 12139739.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    304. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3854-9. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ. PMID: 11891278.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    305. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002 Mar; 43(3):461-6. Burger JA, Kipps TJ. PMID: 12002747.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    306. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002 Feb 01; 99(3):1030-7. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. PMID: 11807009.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    307. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb; 29(1 Suppl 2):98-104. Kipps TJ. PMID: 11842396.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    308. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb; 29(1S2):98-104. PMID: 28140099.
      View in: PubMed   Mentions: 2     Fields:    
    309. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. Biol Blood Marrow Transplant. 2002; 8(10):557-68. Zhong RK, Rassenti LZ, Kipps TJ, Chen J, Law P, Yu JF, Ball ED. PMID: 12434951.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    310. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001 Dec 03; 194(11):1639-47. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. PMID: 11733578.
      View in: PubMed   Mentions: 243     Fields:    Translation:Humans
    311. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol. 2001 Dec; 28(12):2583-90. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps TJ, Hashimoto H. PMID: 11764201.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    312. Biochemical genetic analysis of indanocine resistance in human leukemia. Cancer Res. 2001 Oct 01; 61(19):7248-54. Hua XH, Genini D, Gussio R, Tawatao R, Shih H, Kipps TJ, Carson DA, Leoni LM. PMID: 11585762.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    313. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 2001 Sep 15; 61(18):6640-8. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM. PMID: 11559527.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    314. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia. 2001 Sep; 15(9):1451-7. Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. PMID: 11516107.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    315. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res. 2001 Apr 01; 61(7):2870-7. Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, Rassenti L, Kipps TJ, Bullrich F, Croce CM. PMID: 11306461.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    316. Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine. 2001 Feb 28; 19(15-16):2181-9. Burger JA, Mendoza RB, Kipps TJ. PMID: 11228391.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    317. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest. 2001 Feb; 107(3):305-15. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. PMID: 11160154.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    318. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol. 2001 Jan 01; 166(1):95-102. Widhopf GF, Kipps TJ. PMID: 11123281.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    319. Immunogenetic therapy for B-cell malignancies. Semin Oncol. 2000 Dec; 27(6 Suppl 12):104-9. Kipps TJ, Chu P, Wierda WG. PMID: 11225994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    320. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000 Nov 01; 165(9):5084-96. Zapata JM, Krajewska M, Krajewski S, Kitada S, Welsh K, Monks A, McCloskey N, Gordon J, Kipps TJ, Gascoyne RD, Shabaik A, Reed JC. PMID: 11046039.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    321. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000 Nov 01; 96(9):2917-24. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. PMID: 11049967.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCellsCTClinical Trials
    322. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000 Oct 15; 96(8):2655-63. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. PMID: 11023495.
      View in: PubMed   Mentions: 232     Fields:    Translation:HumansCells
    323. Gene therapy of hematologic malignancies. Semin Oncol. 2000 Oct; 27(5):502-11. Wierda WG, Kipps TJ. PMID: 11049018.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    324. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther. 2000 Jul; 7(7):1051-9. Spear MA, Sun F, Eling DJ, Gilpin E, Kipps TJ, Chiocca EA, Bouvet M. PMID: 10917208.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    325. Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. Gene Ther. 2000 Jul; 7(14):1210-6. Eling DJ, Johnson PA, Sharma S, Tufaro F, Kipps TJ. PMID: 10918489.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    326. Chronic lymphocytic leukemia. Curr Opin Hematol. 2000 Jul; 7(4):223-34. Kipps TJ. PMID: 10882178.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    327. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood. 2000 Jun 15; 95(12):3853-8. Chu P, Wierda WG, Kipps TJ. PMID: 10845920.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    328. Genetics of chronic lymphocytic leukaemia. Hematol Cell Ther. 2000 Jun; 42(1):5-14. Kipps TJ. PMID: 11036944.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    329. Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15; 95(8):2725-7. Rassenti LZ, Kipps TJ. PMID: 10753858.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    330. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol. 2000 Mar; 108(3):641-52. Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. PMID: 10759724.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    331. Limitations of in vivo IL-12 supplementation strategies to induce Th1 early life responses to model viral and bacterial vaccine antigens. Virology. 2000 Mar 01; 268(1):122-31. Kovarik J, Martinez X, Pihlgren M, Bozzotti P, Tao MH, Kipps TJ, Wild TF, Lambert PH, Siegrist CA. PMID: 10683334.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCellsPHPublic Health
    332. Genetic engineering strategies for hematologic malignancies. Genet Eng (N Y). 2000; 22:197-207. Kipps TJ. PMID: 11501377.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    333. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999 Dec 01; 94(11):3658-67. Burger JA, Burger M, Kipps TJ. PMID: 10572077.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansCells
    334. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches. Semin Hematol. 1999 Oct; 36(4 Suppl 5):3-8. Kipps TJ. PMID: 10528909.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    335. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999 Oct; 104(7):947-55. Kato K, Santana-Sahagún E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ. PMID: 10510335.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    336. Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. Cell Immunol. 1999 Jul 10; 195(1):43-52. Hu D, Kipps TJ. PMID: 10433796.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    337. Chronic lymphocytic leukemia. Curr Opin Hematol. 1999 Jul; 6(4):253-61. Wierda WG, Kipps TJ. PMID: 10400375.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    338. Extending genetic vaccines with chemokines. Nat Biotechnol. 1999 Mar; 17(3):226-7. Kipps T, Mendoza R. PMID: 10096284.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    339. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 1999 Jan 01; 59(1):24-7. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, Albitar M, Reed JC, Croce CM. PMID: 9892178.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    340. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998 Oct 15; 102(8):1515-25. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder HW, Ferrarini M, Chiorazzi N. PMID: 9788964.
      View in: PubMed   Mentions: 200     Fields:    Translation:HumansCells
    341. Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood. 1998 Aug 15; 92(4):1317-23. Bessudo A, Rassenti L, Havlir D, Richman D, Feigal E, Kipps TJ. PMID: 9694720.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    342. Chronic lymphocytic leukemia. Curr Opin Hematol. 1998 Jul; 5(4):244-53. Kipps TJ. PMID: 9747630.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    343. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res. 1998 May 01; 58(9):1965-71. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. PMID: 9581840.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    344. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998 Mar 01; 101(5):1133-41. Kato K, Cantwell MJ, Sharma S, Kipps TJ. PMID: 9486984.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    345. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol. 1997 Dec 15; 159(12):5777-81. Mendoza RB, Cantwell MJ, Kipps TJ. PMID: 9550372.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    346. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol. 1997 Dec 15; 159(12):6037-43. Wu Y, Kipps TJ. PMID: 9550402.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    347. Signal transduction pathways and mechanisms of apoptosis in CLL B-lymphocytes: their role in CLL pathogenesis. Hematol Cell Ther. 1997 Nov; 39 Suppl 1:S17-27. Kipps TJ. PMID: 9471058.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    348. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum. 1997 Sep; 40(9):1644-52. Cantwell MJ, Hua T, Zvaifler NJ, Kipps TJ. PMID: 9324019.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    349. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997 Sep; 3(9):984-9. Cantwell M, Hua T, Pappas J, Kipps TJ. PMID: 9288724.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    350. Chronic lymphocytic leukemia. Curr Opin Hematol. 1997 Jul; 4(4):268-76. Kipps TJ. PMID: 9260055.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    351. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med. 1997 Apr 21; 185(8):1435-45. Rassenti LZ, Kipps TJ. PMID: 9126924.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    352. Expression of an Ig VH gene, 51p1, is proportional to its germline gene copy number. Ann N Y Acad Sci. 1997 Apr 05; 815:478-80. Sasso EH, Johnson T, Kipps TJ. PMID: 9186703.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    353. Human B cell biology. Int Rev Immunol. 1997; 15(3-4):243-64. Kipps TJ. PMID: 9222821.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    354. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997 Jan 01; 158(1):235-46. Johnson TA, Rassenti LZ, Kipps TJ. PMID: 8977195.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    355. The human immunoglobulin V(H) gene repertoire is genetically controlled and unaltered by chronic autoimmune stimulation. J Clin Invest. 1996 Dec 15; 98(12):2794-800. Kohsaka H, Carson DA, Rassenti LZ, Ollier WE, Chen PP, Kipps TJ, Miyasaka N. PMID: 8981926.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    356. Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood. 1996 Dec 15; 88(12):4676-83. Cantwell MJ, Sharma S, Friedmann T, Kipps TJ. PMID: 8977261.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    357. Identification of a promoter element that regulates tissue-specific expression of the human CD80 (B7.1) gene. J Immunol. 1996 Nov 15; 157(10):4442-50. Fong TC, Wu Y, Kipps TJ. PMID: 8906820.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    358. Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11842-7. Sharma S, Cantwell M, Kipps TJ, Friedmann T. PMID: 8876225.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    359. What is the CLL B-lymphocyte? Leuk Lymphoma. 1996 Oct; 22 Suppl 2:13-39. Dighiero G, Kipps T, Schroeder HW, Chiorazzi N, Stevenson F, Silberstein LE, Caligaris-Cappio F, Ferrarini M. PMID: 9021706.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    360. Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma. Blood. 1996 Jul 01; 88(1):252-60. Bessudo A, Cherepakhin V, Johnson TA, Rassenti LZ, Feigal E, Kipps TJ. PMID: 8704181.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    361. Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest. 1996 May 01; 97(9):2074-80. Sasso EH, Johnson T, Kipps TJ. PMID: 8621797.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    362. The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells. Blood Cells Mol Dis. 1996; 22(2):126-38. Silberstein LE, George A, Durdik JM, Kipps TJ. PMID: 8931953.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    363. Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Ann N Y Acad Sci. 1995 Sep 29; 764:463-73. Rassenti LZ, Kohsaka H, Kipps TJ. PMID: 7486567.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    364. Origin of high-grade lymphomas in Richter syndrome. Leuk Lymphoma. 1995 Aug; 18(5-6):367-72. Bessudo A, Kipps TJ. PMID: 8528042.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    365. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995 Jun 15; 85(12):3556-65. Ranheim EA, Cantwell MJ, Kipps TJ. PMID: 7540066.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    366. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 01; 161(2):226-35. Ranheim EA, Kipps TJ. PMID: 7535196.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    367. Anti-B cell autoantibodies encoded by VH 4-21 genes in human fetal spleen do not require in vivo somatic selection. Eur J Immunol. 1994 Dec; 24(12):2941-9. Parr TB, Johnson TA, Silberstein LE, Kipps TJ. PMID: 7805720.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    368. Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum. 1994 Nov; 37(11):1637-46. Ranheim EA, Kipps TJ. PMID: 7526869.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    369. X inactivation and immunocompetence in female carriers of the X-linked hyper-IgM syndrome. J Clin Invest. 1994 Aug; 94(2):469. Kipps TJ. PMID: 8040297.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    370. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J Immunol. 1994 Jun 15; 152(12):5988-96. Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL. PMID: 8207223.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    371. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med. 1994 Mar 01; 179(3):999-1004. Lotz M, Ranheim E, Kipps TJ. PMID: 8113691.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    372. Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor. J Immunol. 1993 Dec 15; 151(12):7273-83. Kobayashi R, Rassenti LZ, Meisenholder G, Carson DA, Kipps TJ. PMID: 7505024.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    373. Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome. Blood. 1993 Nov 15; 82(10):3141-7. Cherepakhin V, Baird SM, Meisenholder GW, Kipps TJ. PMID: 7693038.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    374. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science. 1993 Sep 17; 261(5128):1588-91. Berberian L, Goodglick L, Kipps TJ, Braun J. PMID: 7690497.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    375. Induction of antibodies to a kappa V region by gene immunization. J Immunol. 1993 Sep 01; 151(5):2871-6. Watanabe A, Raz E, Kohsaka H, Tighe H, Baird SM, Kipps TJ, Carson DA. PMID: 8360497.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    376. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A. 1993 May 15; 90(10):4523-7. Raz E, Watanabe A, Baird SM, Eisenberg RA, Parr TB, Lotz M, Kipps TJ, Carson DA. PMID: 8506293.
      View in: PubMed   Mentions: 18     Fields:    Translation:Animals
    377. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 1993 May 15; 81(10):2475-87. Kipps TJ, Carson DA. PMID: 8490163.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    378. Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia. J Exp Med. 1993 Apr 01; 177(4):1039-46. Rassenti LZ, Kipps TJ. PMID: 7681468.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    379. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993 Apr 01; 177(4):925-35. Ranheim EA, Kipps TJ. PMID: 7681471.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansAnimalsCells
    380. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993 Feb 01; 81(3):597-601. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. PMID: 8094016.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    381. Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. J Exp Med. 1993 Jan 01; 177(1):109-18. Tighe H, Chen PP, Tucker R, Kipps TJ, Roudier J, Jirik FR, Carson DA. PMID: 8418195.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    382. Gene therapy for cancer. J Hematother. 1993; 2(3):367-72. Kipps TJ. PMID: 7921998.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    383. Immunoglobulin genes in chronic lymphocytic leukemia. Blood Cells. 1993; 19(3):615-25; discussion 631-2. Kipps TJ. PMID: 8018942.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    384. Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res. 1992 Oct 01; 52(19 Suppl):5552s-5553s. Mosier DE, Picchio GR, Baird SM, Kobayashi R, Kipps TJ. PMID: 1327510.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    385. Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. Leuk Res. 1992 Oct; 16(10):1013-23. Kobayashi R, Picchio G, Kirven M, Meisenholder G, Baird S, Carson DA, Mosier DE, Kipps TJ. PMID: 1383641.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    386. An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i blood group specificity on normal human B cells. Eur J Immunol. 1992 Jul; 22(7):1781-8. Grillot-Courvalin C, Brouet JC, Piller F, Rassenti LZ, Labaume S, Silverman GJ, Silberstein L, Kipps TJ. PMID: 1623923.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    387. New developments in flow cytometric analyses of lymphocyte markers. Clin Lab Med. 1992 Jun; 12(2):237-75. Kipps TJ, Meisenholder G, Robbins BA. PMID: 1611820.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    388. Immunoglobulin V gene expression in CD5 B-cell malignancies. Ann N Y Acad Sci. 1992 May 04; 651:373-83. Kipps TJ, Rassenti LZ, Duffy S, Johnson T, Kobayashi R, Carson DA. PMID: 1376056.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    389. EBV-induced human B cell lymphomas in hu-PBL-SCID mice. AIDS Res Hum Retroviruses. 1992 May; 8(5):735-40. Mosier DE, Picchio GR, Kirven MB, Garnier JL, Torbett BE, Baird SM, Kobayashi R, Kipps TJ. PMID: 1325170.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    390. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res. 1992 May 01; 52(9):2468-77. Picchio GR, Kobayashi R, Kirven M, Baird SM, Kipps TJ, Mosier DE. PMID: 1314693.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    391. Evidence for somatic selection of natural autoantibodies. J Exp Med. 1992 Apr 01; 175(4):983-91. Martin T, Duffy SF, Carson DA, Kipps TJ. PMID: 1552291.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    392. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proc Natl Acad Sci U S A. 1992 Apr 01; 89(7):2970-4. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. PMID: 1348362.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    393. Molecular characterization of a supratypic cross-reactive idiotype associated with IgM autoantibodies. J Immunol. 1991 Sep 15; 147(6):2041-6. Pratt LF, Szubin R, Carson DA, Kipps TJ. PMID: 1890310.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    394. Autoantibody-encoding kappa L chain genes frequently rearranged in lambda L chain-expressing chronic lymphocytic leukemia. J Immunol. 1991 Aug 01; 147(3):1060-6. Rassenti LZ, Pratt LF, Chen PP, Carson DA, Kipps TJ. PMID: 1907304.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    395. Relationship of the CD5 B cell to human tonsillar lymphocytes that express autoantibody-associated cross-reactive idiotypes. J Clin Invest. 1991 Jun; 87(6):2087-96. Kipps TJ, Duffy SF. PMID: 1710233.
      View in: PubMed   Mentions: 19     Fields:    Translation:Cells
    396. Idiotypic cross-reactivity of immunoglobulins expressed in Waldenström's macroglobulinemia, chronic lymphocytic leukemia, and mantle zone lymphocytes of secondary B-cell follicles. Blood. 1991 Apr 01; 77(7):1484-90. Axelrod O, Silverman GJ, Dev V, Kyle R, Carson DA, Kipps TJ. PMID: 1901234.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    397. New roles for rheumatoid factor. J Clin Invest. 1991 Feb; 87(2):379-83. Carson DA, Chen PP, Kipps TJ. PMID: 1991824.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    398. Immunoglobulin gene expression in systemic rheumatic diseases. Br J Rheumatol. 1991; 30 Suppl 1:43-6. Carson DA, Chen PP, Silverman GJ, Kipps TJ. PMID: 1991239.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    399. Immunoglobulin Gene Rearrangement and Expression in B-CLL. Leuk Lymphoma. 1991; 5 Suppl 1:39-45. PMID: 27463478.
      View in: PubMed   Mentions:    Fields:    
    400. CD5-positive B-cell malignancies frequently express cross-reactive idiotypes associated with IgM autoantibodies. Am J Pathol. 1990 Apr; 136(4):809-16. Kipps TJ, Robbins BA, Tefferi A, Meisenholder G, Banks PM, Carson DA. PMID: 1691593.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    401. Intraclonal diversity in the VH genes expressed by CD5- chronic lymphocytic leukemia-producing pathologic IgM rheumatoid factor. J Immunol. 1990 Feb 15; 144(4):1526-30. Roudier J, Silverman GJ, Chen PP, Carson DA, Kipps TJ. PMID: 1689356.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    402. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med. 1990 Feb 01; 171(2):559-64. Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. PMID: 2106002.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    403. Immunoglobulin idiotypes in human B cell neoplasia. Implications for pathogenesis and therapy. Chem Immunol. 1990; 48:167-84. Kipps TJ. PMID: 2403805.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    404. EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. Curr Top Microbiol Immunol. 1990; 166:317-23. Mosier DE, Baird SM, Kirven MB, Gulizia RJ, Wilson DB, Kubayashi R, Picchio G, Garnier JL, Sullivan JL, Kipps TJ. PMID: 1963581.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    405. Uniform high frequency expression of autoantibody-associated crossreactive idiotypes in the primary B cell follicles of human fetal spleen. J Exp Med. 1990 Jan 01; 171(1):189-96. Kipps TJ, Robbins BA, Carson DA. PMID: 1688607.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    406. Regulation of rheumatoid factor synthesis. Clin Exp Rheumatol. 1989 Sep-Oct; 7 Suppl 3:S69-73. Carson DA, Chen PP, Kipps TJ, Roudier J, Silverman GJ, Tighe H. PMID: 2691162.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    407. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1989 Aug; 86(15):5913-7. Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. PMID: 2503826.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    408. Ig V region gene expression in small lymphocytic lymphoma with little or no somatic hypermutation. J Immunol. 1989 Jul 15; 143(2):699-705. Pratt LF, Rassenti L, Larrick J, Robbins B, Banks PM, Kipps TJ. PMID: 2661689.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    409. Molecular characterization of a major autoantibody-associated cross-reactive idiotype in Sjogren's syndrome. J Immunol. 1989 Jun 15; 142(12):4261-8. Kipps TJ, Tomhave E, Chen PP, Fox RI. PMID: 2542406.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    410. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989 Jun 01; 49(11):2857-61. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA. PMID: 2720646.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    411. Characterization of four homologous L chain variable region genes that are related to 6B6.6 idiotype positive human rheumatoid factor L chains. J Immunol. 1989 Jan 15; 142(2):688-94. Liu MF, Robbins DL, Crowley JJ, Sinha S, Kozin F, Kipps TJ, Carson DA, Chen PP. PMID: 2492051.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    412. Characterization of two immunoglobulin VH genes that are homologous to human rheumatoid factors. Arthritis Rheum. 1989 Jan; 32(1):72-6. Chen PP, Liu MF, Glass CA, Sinha S, Kipps TJ, Carson DA. PMID: 2492198.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    413. Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency. Curr Top Microbiol Immunol. 1989; 152:195-9. Mosier DE, Gulizia RJ, Baird SM, Spector S, Spector D, Kipps TJ, Fox RI, Carson DA, Cooper N, Richman DD. PMID: 2553338.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    414. The CD5 B cell. Adv Immunol. 1989; 47:117-85. Kipps TJ. PMID: 2479233.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansAnimalsCells
    415. Autoantibody-associated cross-reactive idiotypes expressed at high frequency in chronic lymphocytic leukemia relative to B-cell lymphomas of follicular center cell origin. Blood. 1988 Aug; 72(2):422-8. Kipps TJ, Robbins BA, Kuster P, Carson DA. PMID: 3261179.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    416. Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med. 1988 Mar 01; 167(3):840-52. Kipps TJ, Tomhave E, Chen PP, Carson DA. PMID: 3127527.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    417. Immunoglobulin V gene utilization in chronic lymphocytic leukemia and non-Hodgkin's B cell lymphomas. Nouv Rev Fr Hematol. 1988; 30(5-6):293-8. Kipps TJ. PMID: 3065730.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    418. Autoantibody production in Sjögren's syndrome: a hypothesis regarding defects in somatic diversification of germ line encoded genes. In Vivo. 1988 Jan-Feb; 2(1):47-55. Fox RI, Fong S, Chen PP, Kipps TJ. PMID: 2979816.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    419. Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody. J Immunol. 1987 Dec 01; 139(11):3660-4. Waldor MK, Mitchell D, Kipps TJ, Herzenberg LA, Steinman L. PMID: 3500226.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    420. Idiotypic and genetic studies of human rheumatoid factors. Arthritis Rheum. 1987 Dec; 30(12):1321-5. Carson DA, Chen PP, Kipps TJ, Radoux V, Jirik FR, Goldfien RD, Fox RI, Silverman GJ, Fong S. PMID: 3124859.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    421. Isolation and characterization of a light chain variable region gene for human rheumatoid factors. J Exp Med. 1987 Dec 01; 166(6):1900-5. Chen PP, Robbins DL, Jirik FR, Kipps TJ, Carson DA. PMID: 3119763.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    422. Isolation and characterization of human VkIII germ-line genes. Implications for the molecular basis of human VkIII light chain diversity. J Immunol. 1987 Sep 01; 139(5):1727-33. Chen PP, Albrandt K, Kipps TJ, Radoux V, Liu FT, Carson DA. PMID: 3114376.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    423. Genetic influence on the levels of circulating CD5 B lymphocytes. J Immunol. 1987 Aug 15; 139(4):1060-4. Kipps TJ, Vaughan JH. PMID: 3112220.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    424. High-frequency expression of a conserved kappa light-chain variable-region gene in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1987 May; 84(9):2916-20. Kipps TJ, Fong S, Tomhave E, Chen PP, Goldfien RD, Carson DA. PMID: 3106980.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    425. Genetic analysis of human B cell hybridomas expressing a cross-reactive idiotype. J Immunol. 1987 Feb 01; 138(3):940-4. Goldfien RD, Chen PJ, Kipps TJ, Starkebaum G, Heitzmann JG, Radoux V, Fong S, Carson DA. PMID: 2433336.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    426. Rheumatoid factor and immune networks. Annu Rev Immunol. 1987; 5:109-26. Carson DA, Chen PP, Fox RI, Kipps TJ, Jirik F, Goldfien RD, Silverman G, Radoux V, Fong S. PMID: 2439101.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    427. Molecular basis for the cross-reactive idiotypes on human anti-IgG autoantibodies (rheumatoid factors). Ciba Found Symp. 1987; 129:123-34. Carson DA, Chen PP, Kipps TJ, Radoux V, Jirik F, Goldfien RD, Fox RI, Silverman GJ, Fong S. PMID: 3315499.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    428. Homologous chromosome recombination generating immunoglobulin allotype and isotype switch variants. EMBO J. 1986 Feb; 5(2):263-8. Kipps TJ, Herzenberg LA. PMID: 3519208.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    429. Further studies on the epitopes of HLA-B7 defined by murine monoclonal antibodies. Hum Immunol. 1986 Jan; 15(1):44-67. Parham P, Antonelli P, Herzenberg LA, Kipps TJ, Fuller A, Ward FE. PMID: 2419285.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    430. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med. 1985 Dec 01; 162(6):2089-106. Lanier LL, Kipps TJ, Phillips JH. PMID: 2415663.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    431. The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas. J Immunol. 1985 Jul; 135(1):653-8. Giardina SL, Schroff RW, Kipps TJ, Woodhouse CS, Abrams PG, Rager HC, Morgan AC, Foon KA. PMID: 3873497.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    432. Human bone marrow and peripheral blood T lymphocyte depletion: efficacy and effects of both T cells and monocytes on growth of hematopoietic progenitors. Blood. 1985 Mar; 65(3):663-79. Levitt L, Kipps TJ, Engleman EG, Greenberg PL. PMID: 3871644.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    433. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med. 1985 Jan 01; 161(1):1-17. Kipps TJ, Parham P, Punt J, Herzenberg LA. PMID: 3918141.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    434. The Philadelphia (Ph) chromosome in leukemia. II. Variant Ph translocations in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1985 Jan 01; 14(1-2):11-21. Sandberg AA, Morgan R, Kipps TJ, Hecht BK, Hecht F. PMID: 3855270.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    435. Isolation of heavy chain class switch variants of a monoclonal anti-DC1 hybridoma cell line: effective conversion of noncytotoxic IgG1 antibodies to cytotoxic IgG2 antibodies. Hum Immunol. 1983 Oct; 8(2):141-51. Parham P, Kipps TJ, Ward FE, Herzenberg LA. PMID: 6417068.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    436. Comparison of T and B cell reactivity to antigens under Ir gene control. J Immunol. 1980 Mar; 124(3):1344-9. Kipps TJ, Weinberger JZ, Benacerraf B, Dorf ME. PMID: 6766972.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    437. Shared idiotypic determinants on antibodies and T-cell-derived suppressor factor specific for the random terpolymer L-glutamic acid60-L-alanine30-L-tyrosine10. J Exp Med. 1979 Mar 01; 149(3):613-22. Germain RN, Ju ST, Kipps TJ, Benacerraf B, Dorf ME. PMID: 107261.
      View in: PubMed   Mentions: 50     Fields:    Translation:AnimalsCells
    438. Idiotypic analysis of anti-GAT antibodies. I. Presence of common idiotypic specificities in both responder and nonresponder mice. J Immunol. 1978 Sep; 121(3):1034-9. Ju ST, Kipps TJ, Theze J, Benacerraf B, Dorf ME. PMID: 690432.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    439. H-2 control of the magnitude and heterogeneity of the immune response. Eur J Immunol. 1978 Jun; 8(6):415-23. Kipps TJ, Benacerraf B, Dorf ME. PMID: 668804.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    440. Regulation of antibody heterogeneity by suppressor T cells: diminishing suppressor T cell activity increases the number of dinitrophenyl clones in mice immunized with dinitrophenyl-poly(Glu,Lys,Phe) or dinitrophenyl-poly(Glu,Lys,Ala). Proc Natl Acad Sci U S A. 1978 Jun; 75(6):2914-7. Kipps TJ, Benacerraf B, Dorf ME. PMID: 307250.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    441. [Analysis of the restricted dinitrophenyl (DNP) antibody response to the DNP conjugate of poly-(L-Glu56, L-LYS35, L-PHE9)]. J Immunol. 1978 Jan; 120(1):46-52. Kipps TJ, Benacerraf B, Dorf ME. PMID: 627726.
      View in: PubMed   Mentions: 2     Fields:    
    442. Presence of common idiotypes on antibodies induced by glutamic acid-lysine-containing terpolymers in responder and nonresponder mice with the Ig-1b heavy chain allotype. Eur J Immunol. 1977 Dec; 7(12):865-71. Kipps TJ, Benacerraf B, Dorf ME. PMID: 415884.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    Thomas's Networks
    Concepts (1116)
    Derived automatically from this person's publications.
    _
    Co-Authors (73)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _